Evidence map›Paper›PMID 27270323›Full record

ArticleOncotarget2016

Ellagitannin-rich cloudberry inhibits hepatocyte growth factor induced cell migration and phosphatidylinositol 3-kinase/AKT activation in colon carcinoma cells and tumors in Min mice.

Anne-Maria Pajari, Essi Päivärinta, Lassi Paavolainen, Elina Vaara, Tuuli Koivumäki, Ritu Garg, Anu Heiman-Lindh, Marja Mutanen, Varpu Marjomäki, Anne J Ridley

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. BPA and Nutraceuticals, Simultaneous Effects on Endocrine Functions.Endocrine, metabolic & immune disorders drug targets · 2019
    Review
  6. A Comprehensive Review of the Structure Elucidation of Tannins fromEvidence-based complementary and alternative medicine : eCAM · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Anne-Maria PajariDepartment of Food and Environmental Sciences, Division of Nutrition, University of Helsinki, Helsinki, Finland.
Essi PäivärintaDepartment of Food and Environmental Sciences, Division of Nutrition, University of Helsinki, Helsinki, Finland.
Lassi PaavolainenDepartment of Biological and Environmental Science / Nanoscience Center, University of Jyväskylä, Jyväskylä, Finland.
Elina VaaraDepartment of Food and Environmental Sciences, Division of Nutrition, University of Helsinki, Helsinki, Finland.
Tuuli KoivumäkiDepartment of Food and Environmental Sciences, Division of Food Chemistry, University of Helsinki, Helsinki, Finland.
Ritu GargRandall Division of Cell & Molecular Biophysics, King's College London, New Hunt's House, Guy's Campus, London, UK.
Anu Heiman-LindhDepartment of Food and Environmental Sciences, Division of Nutrition, University of Helsinki, Helsinki, Finland.
Marja MutanenDepartment of Food and Environmental Sciences, Division of Nutrition, University of Helsinki, Helsinki, Finland.
Varpu MarjomäkiDepartment of Biological and Environmental Science / Nanoscience Center, University of Jyväskylä, Jyväskylä, Finland.
Anne J RidleyUniversity College London, Ludwig Institute for Cancer Research, London, UK.
University of Helsinki · FIUniversity of Jyväskylä · FIKing's College London · GBLudwig Cancer Research · GBUniversity College London · GB

Funding

Cancer Research UK 15961
6 · The paper itself

Abstract

Berries have been found to inhibit colon carcinogenesis in animal models, and thus represent a potential source of compounds for prevention and treatment of colorectal cancer. The mechanistic basis for their effects is not well understood. We used human colon carcinoma cells and Min mice to investigate the effects of ellagitannin-rich cloudberry (Rubus chamaemorus) extract on cancer cell migration and underlying cell signaling. Intrinsic and hepatocyte growth factor (HGF) -induced cell motility in human HT29 and HCA7 colon carcinoma cells was assessed carrying out cell scattering and scratch wound healing assays using time-lapse microscopy. Activation of Met, AKT, and ERK in cell lines and tumors of cloudberry-fed Min mice were determined using immunoprecipitation, Western blot and immunohistochemical analyses. Cloudberry extract significantly inhibited particularly HGF-induced cancer cell migration in both cell lines. Cloudberry extract inhibited the Met receptor tyrosine phosphorylation by HGF and strongly suppressed HGF-induced AKT and ERK activation in both HT29 and HCA7 cells. Consistently, cloudberry feeding (10% w/w freeze-dried berries in diet for 10 weeks) reduced the level of active AKT and prevented phosphoMet localization at the edges in tumors of Min mice. These results indicate that cloudberry reduces tumor growth and cancer cell motility by inhibiting Met signaling and consequent activation of phosphatidylinositol 3-kinase/AKT in vitro and in tumors in vivo. As the Met receptor is recognized to be a major target in cancer treatment, our results suggest that dietary phytochemicals may have therapeutic value in reducing cancer progression and metastasis.

Indexed as

AdenocarcinomaAnimalsAntineoplastic AgentsCell Line, TumorCell MovementColonic NeoplasmsEnzyme ActivationHepatocyte Growth FactorHumansHydrolyzable TanninsMiceMice, Inbred C57BLMice, Mutant StrainsPhosphatidylinositol 3-KinasesPlant ExtractsProto-Oncogene Proteins c-aktAntineoplastic AgentsellagitanninHepatocyte Growth FactorHydrolyzable TanninsPhosphatidylinositol 3-KinasesPlant ExtractsProto-Oncogene Proteins c-aktcell migrationcolorectal cancerellagitanninsMet receptorMin mouse

Identifiers

PMID27270323
PMCPMC5190067
OpenAlexW2414043516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.